Twist Bioscience (TWST) just rolled out research grade Plasmid DNA Preps tailored for pre clinical pharma and biotech work, a small but telling move that helps explain the recent uptick in the stock.
In early December 2025, Twist Bioscience launched research-grade Plasmid DNA Preps with animal origin-free and endotoxin-free options tailored to stringent preclinical study requirements. This move ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback